CORT earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeut

2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape

Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeut

Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 – $950 million Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 Cash and investments of $570.8 million as of March 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results "In the first quarter, we had another record number of prescrip

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For

2024 revenue of $675.0 million, a 40 percent increase over 2023 2025 revenue guidance of $900 – $950 million 2024 net income of $141.2 million, a 33 percent increase over 2023 Cash and investments of $603.2 million as of December 31, 2024 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2024. Financial Results "Once again, we had a record number of new Korlym® prescribers and a record number of p

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic

MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 millionNet income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023Cash and investments of $492.5 million as of June 30

MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Inve

MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024. Financial Results Revenue of $146.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $620 – $650 million, from $600 - $630 millionNet income per common share of $0.25 (diluted), compared to $0.14 in first quarter 2023Cash and investments of $451.0 million as of

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Ev

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here.   Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be avai

MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results Revenue of $123.6 million, a 22 percent increase from third quarter 2022Increase in 2023 revenue guidance to $470 - $480 million, from $455 - $470 million Net income per common share of $0.28 (diluted), compared to $0.30 in third quarter 2022 Cash and investments of $414.8 million as of September 30, 20

MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors

MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results Revenue of $117.7 million, a 14 percent increase from second quarter 2022Increase in 2023 revenue guidance to $455 - $470 million, from $435 - $455 million Net income per common share of $0.25 (diluted), compared to $0.24 in second quarter 2022 Cash and investments of $363.3 million as of June 30, 2023Purcha

MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on August 2, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors /

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2023. Financial Results Revenue of $105.7 million, compared to $93.7 million in first quarter 2022 Raised 2023 revenue guidance to $435 - $455 million, from $430 - $450 millionNet income per common share of $0.14 (diluted), compared to $0.20 in first quarter 2022 Cash and investments of $465.1 million as of March 31, 2023Pur

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here.  Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Inves

MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2022. Financial Results Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 2022 revenue of $401.9 million, compared to $366.0 million in 20212023 revenue guidance of $430 – $450 millionFourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth

MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To access the conference call, please dial 877-407-8029 from the United States or +1-201-689-8029 internationally. A replay of the call will be available on the Investors / Events tab of www.corcept.com. About Corcept Therapeutics Corcept has discovered a large portfolio of proprietary compounds that selectively modula

MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2022. Financial Results Revenue of $101.7 million, compared to $96.1 million in third quarter 2021Tightened 2022 revenue guidance of $400 – $410 millionDiluted net income per common share of $0.30, compared to $0.24 in third quarter 2021 Cash and investments of $401.2 million, compared to $382.0 million at June 30, 2022

MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors

MENLO PARK, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2022. Financial Results Revenue of $103.4 million, compared to $91.6 million in second quarter 2021Reiterated 2022 revenue guidance of $400 – $430 millionDiluted net income per common share of $0.24, compared to $0.21 in second quarter 2021 Cash and investments of $382.0 million, compared to $368.1 million at March 31, 2022

MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Inves

MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join Meeting Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 6942208.

MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. Financial Results Fourth quarter revenue of $98.8 million, compared to $85.7 million in fourth quarter 20202021 revenue of $366.0 million, compared to $353.9 million in 20202022 revenue guidance of $400 – $430 millionFourth quarter GAAP net income of $32.1 million, compared to $26.0 million in fourth quarter 2020

MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join Meeting Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The pa

MENLO PARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2021. Financial Results Revenue of $96.1 million, an 11 percent increase from third quarter 2020GAAP diluted net income of $0.24 per share, compared to $0.17 per share in third quarter 2020Non-GAAP diluted net income of $0.30 per share, compared to $0.24 per share in third quarter 2020Cash and investments of $495.2 million, compared

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join Meeting Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 576392

MENLO PARK, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2021. Financial Results Revenue of $91.6 million, compared to $88.6 million in second quarter 2020GAAP diluted net income of $0.21 per share, compared to $0.23 per share in second quarter 2020Non-GAAP diluted net income of $0.30 per share, compared to $0.32 per share in second quarter 2020Cash and investments of $471.6 million, compa

MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join Meeting Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 1482035.